N-PORT filing recap · April 2026
What did ARK Genomic Revolution ETF buy in April 2026?
Reported stock-position changes between this filing and the previous one. These are ARK Genomic Revolution ETF's own holdings, not the firm's.
Stock value
$1.23B
Positions
32
Estimated turnover
18.8%
Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.
Period in review
ARK Genomic Revolution ETF opened new positions in Alamar Biosciences, Biontech, Eli Lilly, and Generate Biomedicines, while exiting Amgen, Standard Biotools, Incyte, Veeva Systems, Vertex Pharmaceuticals, and Caris Life Sciences. The fund added to Tempus Ai and Intellia Therapeutics, and substantially increased Compass Pathways and Genedx Holdings. It trimmed Twist Bioscience, Guardant Health, Butterfly Network, and Ionis Pharmaceuticals, among others.